Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 0.54 |
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD4 | P21917 | 11/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26104235 | 0.84 | OPRM1 (0.46) | DRD3DRD2DRD4OPRM1OPRD1 | |
| SCHEMBL22790441 | 0.83 | OPRM1 (0.60) | DRD3OPRM1OPRD1OPRK1HDAC4 | |
| SCHEMBL6036780 | 0.80 | HDAC4 (0.47) | DRD3DRD2DRD4HDAC4SLC6A4 | |
| SCHEMBL28398971 | 0.77 | OPRM1 (0.65) | DRD3DRD2DRD4OPRM1OPRD1 | |
| SCHEMBL8780436 | 0.76 | POLB (0.43) | HDAC4SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL4903380 | 0.76 | HSD11B1 (0.41) | DRD3DRD2DRD4HDAC4SLC6A4 | |
| SCHEMBL24397743 | 0.76 | DRD2 (0.39) | DRD3DRD2DRD4HDAC4SMN1; SMN2 | |
| SCHEMBL3812202 | 0.76 | HSD11B1 (0.43) | DRD3DRD2DRD4HDAC4SLC6A4 | |
| SCHEMBL7176061 | 0.75 | DRD2 (0.52) | DRD3DRD2DRD4OPRM1HDAC4 | |
| SCHEMBL7490230 | 0.73 | HDAC4 (0.42) | DRD3DRD2DRD4HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | DRD3 100/4885DRD2 61/4885DRD4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.